Items Tagged ‘BCP-ALL’

June 23rd, 2016

Blincyto® Improves Survival in Type of Acute Lymphoblastic Leukemia

By

The immunotherapeutic agent, Blincyto (blinatumomab), improves survival compared to standard therapy among patients with B-cell precursor, Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (BCP-ALL) that has stopped responding to prior therapies. These results were presented at a presidential symposium at the 2016 annual European Hematologic Association (EHA) meeting. Acute lymphoblastic leukemia (ALL) is the most aggressive […]

View full entry

Tags: 2016, Acute Lymphoblastic Leukemia, all, BCP-ALL, blinatumomab, blincyto, EAH, Leukemia, News, TOWER trial


December 16th, 2015

Addition of Rituxan Improves Outcomes in Some Acute Lymphoblastic Leukemias

By

The addition of Rituxan (rituximab) to standard chemotherapy-based regimens improves outcomes among patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) that is CD20-positive. These results were reported at a plenary session at the 2015 annual meeting of the American Society of Hematology in Orlando, Florida. B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is an aggressive type […]

View full entry

Tags: Acute Lymphoblastic Leukemia, B-cell precursor acute lymphoblastic leukemia, BCP-ALL, CD20-positive, Leukemia, News, riruximab, rituxan